NASDAQ: CHEKCheck Cap Ltd Stock
$0.65-0.02 (-2.99%)
Updated Apr 21, 2025
CHEK Price
$0.65
Fair Value Price
$1.51
Market Cap
$3.80M
52 Week Low
$0.56
52 Week High
$3.04
P/E
-0.3x
P/B
0.22x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$14M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CHEK Overview
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CHEK's potential to beat the market
- CHEK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CHEK news, forecast changes, insider trades & much more!
CHEK News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CHEK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHEK ($0.65) is undervalued by 57.01% relative to our estimate of its Fair Value price of $1.51 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CHEK ($0.65) is significantly undervalued by 57.01% relative to our estimate of its Fair Value price of $1.51 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CHEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CHEK due diligence checks available for Premium users.
Valuation
CHEK fair value
Fair Value of CHEK stock based on Discounted Cash Flow (DCF)
Price
$0.65
Fair Value
$1.51
Undervalued by
57.01%
CHEK ($0.65) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CHEK ($0.65) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CHEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CHEK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
35.03x
Market
27.14x
CHEK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.22x
Industry
3.22x
CHEK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CHEK's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CHEK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.1M
Liabilities
$913.0k
Debt to equity
0.05
CHEK's short-term assets ($17.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHEK's short-term assets ($17.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHEK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CHEK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CHEK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHEK vs Diagnostic & Research Stocks
Check Cap Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.